AstraZeneca mentioned on Thursday its COVID-19 antibody drug was 83% efficient in chopping the chance of individuals contracting symptomatic sickness in a six-month follow-up research, cementing the drugmaker’s lead in growing preventative coronavirus remedies.
The Anglo-Swedish firm mentioned a separate research in sufferers with mild-to-moderate COVID-19 confirmed {that a} increased dose of the remedy, AZD7442, reduce the chance of signs worsening by 88% when given inside three days of first signs.
The most recent spherical of constructive outcomes doubtlessly place AstraZeneca as a uncommon provider of each COVID-19 vaccines and coverings, with the drugmaker having mentioned the remedy’s “actual benefit” was as a preventative shot, moderately than as a therapy.
(Reuters)